LNMAC Promotes Cervical Squamous Cell Carcinoma Lymphatic Metastasis via Epigenetic Regulation of FGF2‐Induced Lymphangiogenesis

• Published in: Advanced science 2024-10, Vol.11 (38), p.e2404645-n/a
• Main Authors: Zhang, Chunyu, Yuan, Li, Wen, Weijia, Shao, Caixia, Liao, Yuandong, Jia, Yan, Zhao, Xueyuan, Liao, Yan, Xu, Dingze, Chen, Linna, Yang, Guofen, Jiang, Hongye, Wang, Wei, Yao, Shuzhong
• Format: Article
• Language: English
• Subjects: Cervical cancer; cervical squamous cell carcinoma; FGF2; Growth factors; LNMAC; lymph node metastasis; lymphangiogenesis; Lymphatic system; Medical prognosis; Metastasis; Tumors
• ISSN: 2198-3844; 2198-3844
• DOI: 10.1002/advs.202404645

The lymph node is the most common site of distant metastasis of cervical squamous cell carcinoma (CSCC), which elicits dismal prognosis and limited efficiency for treatment. Elucidation of the mechanisms underlying CSCC lymphatic metastasis would provide potential therapeutic strategies for nodal metastatic of CSCC. Here, based on in vivo lymphatic metastasis screening model, a circular RNA is identified that is termed as lymph node metastasis associated circRNA (LNMAC), is markedly upregulated in lymphatic metastatic CSCC and correlated with lymph node metastasis. Overexpression of LNMAC dramatically augments the metastatic capability of CSCC cells to the lymph node via inducing lymphangiogenesis. Mechanistically, LNMAC epigenetically upregulates fibroblast growth factor 2 (FGF2) expression by directly associating with histone acacetylase 1 (HDAC1), preventing Importin α6/8‐mediated nuclear translocation of HDAC1 and eliciting histone H3K27ac‐induced FGF2 transcriptional activation. Treatment with 3F12E7, an anti‐FGF2 monoclonal antibody, effectively inhibits LNMAC‐induced CSCC lymphatic metastasis. Taken together, these findings indicate that LNMAC plays a crucial role in FGF2‐mediated lymphangiogenesis and lymphatic metastasis, highlighting that LNMAC might be a therapeutic target for lymph node metastasis in CSCC patients. Cervical squamous cell carcinoma (CSCC) cells mainly metastasize to the lymph nodes. This study reveals that LNMAC dramatically augments CSCC lymphangiogenesis and lymphatic metastasis by binding with histone deacetylase 1 (HDAC1), preventing Importin α6/8‐mediated HDAC1 nuclear translocation and eliciting histone H3K27ac‐induced fibroblast growth factor 2 (FGF2) transcriptional activation. Treatment with 3F12E7 effectively inhibits LNMAC‐induced CSCC lymphatic metastasis in preclinical models.